EXORPHIA is a drug discovery startup that focuses on the potential of exosomes as new treatment options for intractable diseases. The company has developed proprietary core technologies in each process of culture, purification, analysis, and pharmacological evaluation and has established a technological foundation that enables mass production and quality control of exosomes at a pharmaceutical level.
Utilizing exosomes' natural drug delivery capabilities, the company will generate solutions for unresolved health challenges, thereby committing to continuously enhancing corporate value.
Company Details
- Employees
- 7
- Founded
- -
- Address
- Otemachi1-6-1, Otemachi Building 6f #668,japan
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://exorphia.com/en/
- HQ
- Chiyoda-Ku, Tokyo
Exorphia, Inc. Questions
Exorphia, Inc.'s website is https://exorphia.com/en/
Exorphia, Inc.'s LinkedIn profile is https://jp.linkedin.com/company/exorphia-inc
Exorphia, Inc. has
7 employees.
View email and phone details for 7
employees at Exorphia, Inc..
Exorphia, Inc.'s industry is
Biotechnology Research
Exorphia, Inc.'s top competitors are
Carbgem Inc.,
Metagen Therapeutics, Inc.,
Nextgem-Inc,
Peak Technology Partners,
Ugandan Women In Ai,
Bytedance,
Bristol Myers Squibb,
Shinobi Therapeutics.
Exorphia, Inc.'s categories are Biotechnology Research
Exorphia, Inc.'s founding year is 2019
